Usted buscó: bile salt (Inglés - Maltés)

bile
likwidu tal-marrara

bile acid
aċidu biljari

bile problems
problem fil-marrara

bile salt-sequestering agents
sustanzi li jissekwestraw il-melħ tal-bili

primary bile acid
aċidu biljari primarju

bile duct disorders,
disturbi fil-kanal tal-bili, ħsara

blockage of bile ducts
imblukkar tal-passaġġ biljari

inflammation of the bile duct;
infjammazzjoni tal-passaġġ tal-marrara;

inflammation of the bile ducts
infjammazzjoni tal-kanali tal-bila

decrease in bile flow from the liver
tnaqqis fil-fluss tal-bili mill-fwied

intact igg is also excreted in bile.
igg intatt jiġi eskretat ukoll fil-bile.

cholestagel predominantly binds hydrophobic bile acids.
cholestagel, primarjament jwaħħal aċidi idrofobiċi tal-bila.

both glibenclamide and bosentan inhibit the bile salt export pump, which could explain the elevated aminotransferases.
kemm glibenclamide kif ukoll bosentan jimpedixxu l-bile salt export pump, u dan jista’ jispjega għaliex il-livell ta’ aminotranferases jiżdied.

- liver failure, narrowing of the bile vessel
fwied ma jaħdimx, djuq tal- kanal tal- bili

increased bile pigment in the blood (hyperbilirubinaemia)
żieda fil-pigment biljari fid-demm (iperbilirubinemja)

bile duct stone, cholecystitis, hepatitis, jaundice, liver disorder
disturbi fil-fwied, epatite, ġebla fil-marrara, koleċistite, suffejra

administered orally, bile acids and salts generally have only a minor toxic potential.
mogħtija oralment, l-aċidi biljari u komponenti tagħhom mal-melħ ġeneralment ikollhom potenzjal tossiku żgħir ħafna.

these increases may be partly due to competitive inhibition of the elimination of bile salts from hepatocytes but other mechanisms, which have not been clearly established, are probably also involved in the occurrence of liver dysfunction.
parti minn din iż-żieda tista’ tkun parzjalment minħabba l-inibizzjoni kompetittiva ta’ l-eliminazzjoni tal-bile salts mill-hepatocytes, iżda mekkaniżmi oħrajn, li ma kienux stabbiliti b’mod ċar, huma wkoll involuti ma’ funzjoni ħażina tal-fwied.

additional in vitro studies in rat and human hepatocytes showed that ambrisentan did not inhibit sodium-taurocholate co-transporter (ntcp), organic anion export pump (oatp), bile salt export pump (bsep) and multi-drug resistance protein isoform-2 (mrp2).
studji oħra in vitro f' ċelloli tal- fwied fil- far u fil- bniedem urew li ambrisentan ma inibixxix il- ko- trasportatur ta 'sodium taurocholate (ntcp), il- pompa organika ta' esportazzjoni anjonika (oatp), il- pompa ta 'esportazzjoni tal- melħ tal- bil (bsep) u l- isoform 2 tal- proteina ta' reżistenza għal- mediċini multipli (mrp2).